XML 32 R20.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information
9 Months Ended
Sep. 30, 2025
Segment Information  
Segment Information

14. Segment Information

We operate as a single business segment focused on revolutionizing care for patients with challenging respiratory and vascular diseases such as PAH and PH-ILD. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by our Chief Executive Officer, the chief operating decision maker (“CODM”), in assessing segment performance and deciding how to allocate resources on a consolidated basis. The accounting policies of the segment are the same as those described in the summary of significant accounting policies.

The CODM measures segment profit and loss by net loss as reported in the consolidated income statements. The CODM uses net loss to monitor budget and forecast versus actual results to assess segment performance and to allocate resources across the organization. The measure of segment assets is reported on the consolidated balance sheet as total assets.

The following table summarizes segment revenue, segment loss, and significant segment expenses regularly reported to the CODM during the three and nine months ended September 30, 2025 and 2024:

Three Months Ended September 30, 

Nine Months Ended September 30, 

2025

2024

2025

2024

Revenues:

Product sales, net

$

51,669

$

$

58,186

$

Service revenue, net

2,673

4,448

8,113

11,079

Total revenue

54,342

4,448

66,299

11,079

Cost of product sales

2,295

2,500

Cost of service revenue

878

1,565

3,687

4,525

Program expenses (1)

YUTREPIA

15,487

7,972

39,906

18,994

L606

3,199

1,693

9,260

4,928

Generic Treprostinil

21

152

297

596

Total program expenses

18,707

9,817

49,463

24,518

Non-program expenses (2)

 

6,705

 

5,218

 

16,310

 

19,303

Personnel, including stock-based compensation

23,990

17,037

65,502

47,920

Income (loss) from operations

 

1,767

 

(29,189)

 

(71,163)

 

(85,187)

Other income (expense), net

 

(5,300)

 

(1,841)

 

(12,316)

 

(4,594)

Net loss

$

(3,533)

$

(31,030)

$

(83,479)

$

(89,781)

(1)Includes external research and development and selling, general and administrative expenses
(2)Includes professional service fees, facilities & infrastructure expenses, insurance, depreciation & amortization, and other corporate expenses